What’s New Series: Allergy and Immunology

In this episode of TransplantRPh, April introduces the new 'What's New' series, covering the latest advancements in allergy and immunology. From new treatments for COPD and eosinophilic esophagitis to breakthroughs in gene editing therapy for hereditary angioedema, stay updated with the most recent findings. Connect with April via email at aprilfortinoliveros, and follow her on LinkedIn, YouTube, and Instagram. Detailed Notes: Ensifentrine for COPD: Approved for stable COPD, improves bronchodilation, dyspnea, and reduces exacerbations. - Dupilumab for COPD: Reduces exacerbations in patients with high eosinophil counts, potential for those with persistent symptoms. - Benralizumab for EoE: Achieves high histologic remission rates, need for more biomarkers. - Omalizumab for Food Allergies: Approved to reduce reactions from accidental exposures, requires regular injections. - Mavorixafor for WHIM Syndrome: Reduces infection severity and increases white blood cell counts. - Anti-IL-23 Antibodies: Correlate with severe infections in thymoma patients, potential treatment avenues. - Allergic Rhinitis in Childhood: Steady increase in prevalence up to age 16, highlights early diagnosis importance. - Systemic Symptoms in CSU: Common in chronic spontaneous urticaria, necessitates comprehensive management. - NTLA-2002 for HAE: Gene editing therapy significantly reduces angioedema attacks, promising new treatment.